

### COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



## SYNDROMIC MULTIPLEX DIAGNOSTIC MARKETS with COVID-19 IMPACTS.

Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place and by Product. With Market Analysis, Executive Guides and Customization. 2021 to 2025





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1 Market Guides .....22

1.1 Situation Analysis & COVID Impact Overview ..... 23

1.2 Guide for Executives and Marketing Staff ..... 26

1.3 Guide for Investment Analysts and Management Consultants ..... 28

1.4 Market Shares of Leading Companies – Table and Chart ..... 29

2 Introduction and Market Definition .....31

2.1 What are Syndromic Multiplex Tests? ..... 32

2.2 Syndromic Testing – the quiet revolution in diagnostics ..... 33

2.2.1 Syndromic Testing – more than Panels. .... 34

2.3 Market Definition ..... 35

2.3.1 Multiplex Market Size. .... 35

2.3.2 Currency. .... 35

2.3.3 Years. .... 36

2.4 Methodology..... 37

2.4.1 Authors ..... 37

2.4.2 Sources ..... 37

2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic ..... 38

2.5.1 Global Healthcare Spending ..... 38

2.5.2 Spending on Diagnostics ..... 40

2.5.3 Important Role of Insurance for Diagnostics ..... 41

3 The Infectious Diseases – Guide to the Pathogens.....42

3.1 The Coronavirus..... 43

3.1.1 Severe acute respiratory syndrome (SARS) ..... 45

- 3.1.2 Middle East respiratory syndrome (MERS) ..... 47
- 3.1.3 COVID-19. The SARS CoV 2 Virus..... 48
  - 3.1.3.1 Signs and symptoms ..... 49
  - 3.1.3.2 Transmission ..... 50
  - 3.1.3.3 Diagnosis ..... 51
  - 3.1.3.4 Prevention ..... 53
  - 3.1.3.5 Management..... 54
  - 3.1.3.6 Prognosis..... 55
  - 3.1.3.7 New Strains and Subsequent Mutations ..... 56
- 3.2 HIV - Human Immunodeficiency Virus (AIDS) ..... 57
  - 3.2.1 Virology ..... 57
    - 3.2.1.1 Classification ..... 57
    - 3.2.1.2 Structure and genome..... 58
    - 3.2.1.3 Tropism..... 60
    - 3.2.1.4 Replication cycle..... 63
    - 3.2.1.5 Genetic variability ..... 68
  - 3.2.2 Diagnosis ..... 70
  - 3.2.3 Testing..... 71
    - 3.2.3.1 Antibody tests ..... 71
    - 3.2.3.2 Point of Care Tests (POCT) ..... 74
    - 3.2.3.3 Antigen Tests ..... 77
    - 3.2.3.4 Nucleic acid-based tests (NAT) ..... 77
    - 3.2.3.5 Other tests used in HIV treatment..... 78
- 3.3 HBV – Hepatitis B..... 80
  - 3.3.1 Virology ..... 81
    - 3.3.1.1 Genome ..... 82

- 3.3.1.2 Pathogenesis..... 83
- 3.3.1.3 Hepatitis B virus replication ..... 83
- 3.3.1.4 Serotypes and genotypes..... 84
- 3.3.2 Mechanisms..... 84
- 3.3.3 Diagnosis ..... 85
- 3.3.4 Market Opportunity Analysis ..... 86
- 3.4 HCV – Hepatitis C..... 88
  - 3.4.1 Taxonomy..... 89
    - 3.4.1.1 Structure ..... 89
    - 3.4.1.2 Genome ..... 90
  - 3.4.2 Molecular biology ..... 91
  - 3.4.3 Replication..... 92
  - 3.4.4 Genotypes ..... 94
    - 3.4.4.1 Clinical importance ..... 94
  - 3.4.5 Market Opportunity Analysis ..... 95
- 3.5 2.4 HPV - Human papillomavirus..... 96
  - 3.5.1 Virology ..... 98
    - 3.5.1.1 E6/E7 proteins..... 98
    - 3.5.1.2 Role in cancer..... 98
    - 3.5.1.3 E2 research..... 99
    - 3.5.1.4 Latency period ..... 100
    - 3.5.1.5 Clearance ..... 100
  - 3.5.2 Diagnosis ..... 101
    - 3.5.2.1 Cervical testing ..... 101
    - 3.5.2.2 Oral testing ..... 103
    - 3.5.2.3 Testing men ..... 103

- 3.5.2.4 Other testing ..... 104
- 3.5.3 Market Opportunity Analysis ..... 105
- 3.6 Influenza..... 111
  - 3.6.1 Virology ..... 112
    - 3.6.1.1 Types of virus ..... 112
    - 3.6.1.2 Influenzavirus A ..... 112
    - 3.6.1.3 Influenzavirus B ..... 113
    - 3.6.1.4 Influenzavirus C ..... 113
    - 3.6.1.5 Structure, properties, and subtype nomenclature ..... 114
    - 3.6.1.6 Replication ..... 115
  - 3.6.2 Testing..... 117
    - 3.6.2.1 Advantages/Disadvantages of Molecular Assays..... 119
  - 3.6.3 Market Opportunity Analysis ..... 120
- 3.7 CTGC - Chlamydia/Gonorhea ..... 128
  - 3.7.1 Gonorrhoea ..... 128
    - 3.7.1.1 Diagnosis ..... 129
    - 3.7.1.2 Screening ..... 129
  - 3.7.2 Chlamydia ..... 129
    - 3.7.2.1 Diagnosis ..... 130
    - 3.7.2.2 Screening ..... 131
  - 3.7.3 Testing..... 132
    - 3.7.3.1 Nucleic acid amplification tests (NAATs)..... 132
    - 3.7.3.2 Performance of NAAT Tests..... 140
  - 3.7.4 Market Opportunity Analysis ..... 141
- 3.8 Tuberculosis..... 143
  - 3.8.1 Mycobacteria..... 144

- 3.8.2 Diagnosis ..... 145
  - 3.8.2.1 Active tuberculosis ..... 145
  - 3.8.2.2 Latent tuberculosis..... 146
- 3.8.3 Epidemiology ..... 146
- 3.8.4 Molecular Diagnostic Tests ..... 148
- 3.8.5 Market Opportunity Analysis ..... 149
- 3.9 MRSA - Methicillin-resistant Staphylococcus aureus ..... 151
  - 3.9.1 Diagnosis ..... 151
  - 3.9.2 FDA Approved Molecular Tests ..... 152
  - 3.9.3 Market Opportunity Analysis ..... 153
- 3.10 VRE - Vancomycin-resistant Enterococcus ..... 154
  - 3.10.1 FDA Approved MDx Tests for VRE..... 155
  - 3.10.2 Market Opportunity Analysis ..... 156
- 4 Industry Overview.....157
  - 4.1 Industry Participants ..... 158
    - 4.1.1 IVD Supplier..... 158
    - 4.1.2 Independent lab specialized/esoteric ..... 159
    - 4.1.3 Independent lab national/regional..... 159
    - 4.1.4 Independent lab analytical ..... 160
    - 4.1.5 Public National/regional lab ..... 160
    - 4.1.6 Hospital lab ..... 160
    - 4.1.7 Physician lab ..... 161
    - 4.1.8 Audit body ..... 161
  - 4.2 The Clinical Laboratory Market Segments ..... 163
    - 4.2.1 Traditional Market Segmentation..... 163
    - 4.2.2 Laboratory Focus and Segmentation..... 164



- 4.2.3 Segmenting the Syndromic Testing Market..... 165
- 4.3 Industry Structure..... 167
  - 4.3.1 Hospital Testing Share ..... 167
  - 4.3.2 Economies of Scale..... 167
    - 4.3.2.1 Hospital vs. Central Lab..... 168
  - 4.3.3 Physician Office Lab's..... 169
  - 4.3.4 Physician's and POCT ..... 169
- 5 Market Trends ..... 171
  - 5.1 Factors Driving Growth ..... 172
    - 5.1.1 Speed of Diagnosis..... 172
    - 5.1.2 Effect of Syndromic Testing on Costs..... 173
    - 5.1.3 Point of Care Advantage..... 173
    - 5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk..... 173
    - 5.1.5 Single Visits. .... 173
    - 5.1.6 Improvement in Outcomes. .... 174
    - 5.1.7 Impact of the COVID-19 Pandemic. .... 174
  - 5.2 Factors Limiting Growth ..... 175
    - 5.2.1 Lower Prices. .... 175
    - 5.2.2 Administration/reimbursement..... 176
    - 5.2.3 Infectious Disease is Declining But..... 178
    - 5.2.4 Wellness Hurts..... 178
    - 5.2.5 Economic Growth improves Living Standards. .... 178
    - 5.2.6 Impact of the Pandemic Recession ..... 179
  - 5.3 Instrumentation and Automation ..... 180
    - 5.3.1 Instruments Key to Market Share ..... 180
    - 5.3.2 The Shrinking Machine. .... 180

- 5.3.3 Syndrome Testing Moving to Big Instruments? ..... 181
- 5.4 Diagnostic Technology Development ..... 181
  - 5.4.1 Comparing Syndrome and Targeted Testing ..... 182
  - 5.4.2 The Multiplex Paradigm Shift..... 183
  - 5.4.3 The Sepsis Testing Market – Bellwether for Syndromics..... 184
  - 5.4.4 The Single Visit and AntiMicrobial Resistance ..... 184
  - 5.4.5 Syndromics drives POCT adoption..... 185
  - 5.4.6 A Big Future for PCR? ..... 185
- 6 Syndromic Testing Recent Developments .....187
  - 6.1 Recent Developments – Importance and How to Use This Section ..... 188
    - 6.1.1 Importance of These Developments ..... 188
    - 6.1.2 How to Use This Section..... 188
  - 6.2 Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel ..... 188
  - 6.3 QuantumDx Gets CE Mark for Rapid PoC PCR System ..... 189
  - 6.4 Bio-Rad Laboratories, Seegene Partner for MDx Development ..... 190
  - 6.5 Baebies to Expand Finder Platform ..... 191
  - 6.6 With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio ..... 194
  - 6.7 Binx Health Targeting Clinics, DTC & OTC With STI Tests ..... 198
  - 6.8 Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV ..... 202
  - 6.9 Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic ..... 203
  - 6.10 MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test ..... 207
  - 6.11 New Approach Involves Silicon-Based Test for Infectious Disease Screening..... 208
  - 6.12 Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test ..... 212
  - 6.13 Qiagen sees NeuMoDx as Growth Vehicle ..... 215
  - 6.14 Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround..... 219
  - 6.15 Roche, Speedx Partner to Expand Access to Antibiotic Resistance Tests ..... 223

6.16 BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU ..... 224

6.17 Infectious Disease Testing Firm Curative Acquires KorvaLabs ..... 225

6.18 ChromaCode Raises Additional \$10M ..... 225

6.19 COVID-19 Patients Need Syndromic Testing..... 226

6.20 GenMark Diagnostics – New Respiratory Panel due in June..... 227

6.21 Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark..... 229

6.22 Exact Diagnostics launches respiratory panel control ..... 230

6.23 bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA ..... 230

6.24 Nanomix Receives CE Mark for Diagnostic ..... 232

6.25 Applied BioCode Applies to FDA for Syndromic Respiratory Panel ..... 233

6.26 Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC ..... 234

6.27 QIAGEN's New GI Panel Performance Assessed ..... 235

6.28 McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA ..... 236

6.29 Applied BioCode Obtains FDA Clearance ..... 237

6.30 Meridian Bioscience to Acquire GenePOC Inc..... 238

6.31 Curetis Introduces Rapid DNA Testing for Antibiotic Resistance ..... 239

6.32 Qiagen gets FDA clearance for syndromic testing system ..... 240

6.33 Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux ..... 241

6.34 Akonni Biosystems Submits Multiplex Diagnostics System to FDA ..... 242

6.35 Ador Diagnostic to receive \$30M in Funding for 100-Plex PoC ..... 243

6.36 SAW Diagnostics Receives Funding for Commercialisation of PoC Platform..... 244

6.37 QuantuMDx and Molbio announce MoU ..... 246

6.38 Immunexpress Wins \$745K Contract for Rapid Sepsis Assay ..... 248

6.39 Mobidiag Inks European, Middle Eastern Distribution Deals..... 248

6.40 BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial ..... 249

7 Profiles of Key Syndromic Testing Companies .....251

7.1 Abacus Diagnostica ..... 252

7.2 Abbott Diagnostics ..... 253

7.3 Accelerate Diagnostics ..... 255

7.4 Ador Diagnostics ..... 256

7.5 Akonni Biosystems ..... 257

7.6 Alveo Technologies..... 258

7.7 Antelope Dx..... 259

7.8 Applied BioCode ..... 260

7.9 Aus Diagnostics ..... 261

7.10 Baebies ..... 262

7.11 Beckman Coulter Diagnostics..... 264

7.12 Becton, Dickinson and Company ..... 265

7.13 Binx Health ..... 267

7.14 Biocartis..... 269

7.15 BioFire Diagnostics (bioMérieux) ..... 270

7.16 bioMérieux Diagnostics..... 272

7.17 Bio-Rad Laboratories, Inc..... 274

7.18 Bosch Healthcare Solutions GmbH..... 276

7.19 Cepheid (Danaher) ..... 277

7.20 Credo Diagnostics Biomedical ..... 279

7.21 Cue Health..... 280

7.22 Curetis N.V. / Curetis GmbH ..... 282

7.23 Diagenode Diagnostics ..... 283

7.24 Diasorin S.p.A. .... 284

7.25 Enzo Life Sciences, Inc. .... 286

7.26 Eurofins Scientific ..... 288

7.27	Fluxergy .....	290
7.28	Fusion Genomics .....	291
7.29	Genetic Signatures.....	293
7.30	GenMark Dx (Roche) .....	294
7.31	Hibergene Diagnostics.....	296
7.32	Hologic .....	297
7.33	Immunexpress.....	299
7.34	Inflammatix .....	300
7.35	Invetech.....	301
7.36	Janssen Diagnostics .....	302
7.37	Karius .....	303
7.38	Lexagene .....	305
7.39	LightDeck Diagnostics .....	306
7.40	Lucira Health.....	307
7.41	Luminex Corp .....	308
7.42	Maxim Biomedical .....	310
7.43	Meridian Bioscience.....	311
7.44	Mesa Biotech (Thermo Fisher) .....	313
7.45	Millipore Sigma .....	314
7.46	Mobidiag (Hologic).....	315
7.47	Molbio Diagnostics.....	316
7.48	Nanomix.....	317
7.49	Novel Microdevices .....	318
7.50	Operon.....	319
7.51	Oxford Nanopore Technologies .....	320
7.52	Panagene.....	321

7.53	Perkin Elmer.....	322
7.54	Primerdesign (Novacyt) .....	324
7.55	Prominex .....	325
7.56	Qiagen Gmbh .....	326
7.57	Quantumdx .....	328
7.58	Quidel.....	329
7.59	Roche Molecular Diagnostics .....	331
7.60	Saw Diagnostics .....	333
7.61	Seegene.....	334
7.62	Siemens Healthineers .....	336
7.63	Sona Nanotech .....	338
7.64	Speedx.....	339
7.65	T2 Biosystems.....	340
7.66	Talis Biomedical .....	341
7.67	Thermo Fisher Scientific Inc.....	342
7.68	Veramarx .....	344
7.69	Visby Medical .....	345
7.70	XCR Diagnostics .....	347
8	The Global Market for Syndromic Multiplex Diagnostics.....	348
8.1	Global Market Overview by Country .....	349
8.1.1	Table – Global Market by Country.....	349
8.1.2	Chart - Global Market by Country .....	350
8.2	Global Market by Syndrome - Overview .....	351
8.2.1	Table – Global Market by Syndrome .....	351
8.2.2	Chart – Global Market by Syndrome – Base/Final Year Comparison .....	352
8.2.3	Chart – Global Market by Syndrome – Base Year .....	353

8.2.4 Chart – Global Market by Syndrome – End Year..... 354

8.2.5 Chart – Global Market by Syndrome – Share by Year ..... 355

8.2.6 Chart – Global Market by Syndrome – Segments Growth..... 356

8.3 Global Market by Place - Overview ..... 357

8.3.1 Table – Global Market by Place..... 357

8.3.2 Chart – Global Market by Place – Base/Final Year Comparison ..... 358

8.3.3 Chart – Global Market by Place – Base Year..... 359

8.3.4 Chart – Global Market by Place – End Year ..... 360

8.3.5 Chart – Global Market by Place – Share by Year..... 361

8.3.6 Chart – Global Market by Place – Segments Growth ..... 362

8.4 Global Market by Product - Overview ..... 364

8.4.1 Table – Global Market by Product..... 364

8.4.2 Chart – Global Market by Product – Base/Final Year Comparison..... 365

8.4.3 Chart – Global Market by Product – Base Year..... 366

8.4.4 Chart – Global Market by Product – End Year ..... 367

8.4.5 Chart – Global Market by Product – Share by Year ..... 368

8.4.6 Chart – Global Market by Product – Segments Growth ..... 369

9 Global Syndromic Multiplex Markets – By Syndrome .....370

9.1 Respiratory ..... 371

9.1.1 Table Respiratory – by Country ..... 371

9.1.2 Chart - Respiratory Growth..... 372

9.2 Gastrointestinal..... 373

9.2.1 Table Gastrointestinal – by Country ..... 373

9.2.2 Chart - Gastrointestinal Growth ..... 374

9.3 Blood ..... 375

9.3.1 Table Blood – by Country ..... 375

- 9.3.2 Chart - Blood Growth..... 376
- 9.4 Meningitis/Encephalitis ..... 377
  - 9.4.1 Table Meningitis/Encephalitis – by Country..... 377
  - 9.4.2 Chart - Meningitis/Encephalitis Growth ..... 378
- 9.5 Sexually Transmitted Disease..... 379
  - 9.5.1 Table Sexually Transmitted Disease – by Country ..... 379
  - 9.5.2 Chart – Sexually Transmitted Disease Growth ..... 380
- 9.6 Other Syndrome ..... 381
  - 9.6.1 Table Other – by Country ..... 381
  - 9.6.2 Chart - Other Growth..... 382
- 10 Global MDx Infectious Disease Markets – by Place .....383
  - 10.1 Hospital Lab ..... 384
    - 10.1.1 Table Hospital Lab – by Country ..... 384
    - 10.1.2 Chart - Hospital Lab Growth..... 385
  - 10.2 Outpatient Lab..... 386
    - 10.2.1 Table Outpatient Lab – by Country ..... 386
    - 10.2.2 Chart - Outpatient Lab Growth ..... 387
  - 10.3 Point of Care..... 388
    - 10.3.1 Table Point of Care – by Country..... 388
    - 10.3.2 Chart – Point of Care Growth..... 389
  - 10.4 Other Place ..... 390
    - 10.4.1 Table Other – by Country ..... 390
    - 10.4.2 Chart - Other Place Growth ..... 391
- 11 Global MDx Infectious Disease Markets – by Product .....392
  - 11.1 Instruments..... 393
    - 11.1.1 Table Instruments – by Country ..... 393



- 11.1.2 Chart - Instruments Growth..... 394
- 11.2 Cartridges ..... 395
  - 11.2.1 Table Cartridges – by Country ..... 395
  - 11.2.2 Chart - Cartridges Growth..... 396
- 11.3 Reagents..... 397
  - 11.3.1 Table Reagents – by Country ..... 397
  - 11.3.2 Chart - Reagents Growth ..... 398
- 11.4 Other Product..... 399
  - 11.4.1 Table Other Product – by Country ..... 399
  - 11.4.2 Chart – Other Product Growth..... 400
- 12 Appendices.....401
  - 12.1 United States Medicare System: 2021 Clinical Laboratory Fees Schedule ..... 402

Table of Tables

Table 1 Market Share of Leading Companies ..... 29

Table 2 Characteristics of Coronavirus Pandemic Infections ..... 48

Table 3 COVID-19 Symptoms..... 50

Table 4 Classification of HIV Species..... 58

Table 5 HBV Tests - CMS Codes & Prices ..... 88

Table 6 HCV Tests - CMS Codes & Prices ..... 95

Table 7 HPV Clearance Rates ..... 101

Table 8 HPV Tests - CMS Codes & Prices..... 106

Table 9 HPV Tests, Technology, Types ..... 107

Table 10 Types of Influenza Tests ..... 117

Table 11 Influenza Tests - CMS Codes & Prices..... 120

Table 12 FDA Cleared Molecular Assays for Influenza ..... 121

Table 13 FDA Cleared NAAT CTGC Tests ..... 133

Table 14 CTGC NAAT Target Sequences and Possible False Reactions ..... 138

Table 15 Influenza Tests - CMS Codes & Prices..... 142

Table 16 FDA Approved MDx Tests for Tuberculosis ..... 148

Table 17 Tuberculosis Tests - CMS Codes & Prices..... 149

Table 18 FDA Approved Tests for MRSA ..... 152

Table 19 MRSA Tests - CMS Codes & Prices ..... 154

Table 20 FDA Approved Tests for VRE ..... 155

Table 21 VRE Tests - CMS Codes & Prices ..... 156

Table 22 Market Players by Type ..... 158

Table 23 Clinical Laboratory Departments and Segments ..... 163

Table 24 Laboratory Management Focus – Different Approaches ..... 164

Table 25 Key Segmentation Variables Going Forward..... 165

Table 26 Possible Market Segments of Syndromic Multiplex Market ..... 165

Table 27 Five Factors Driving Growth ..... 172

Table 28 How SMT Improves Outcomes..... 174

Table 29 Four Factors Limiting Growth ..... 175

Table 30 - Global Market by Region ..... 349

Table 31 Global Market by Syndrome ..... 351

Table 32 Global Market by Place..... 357

Table 33 Global Market by Product..... 364

Table 34 Respiratory by Country..... 371

Table 35 Gastrointestinal by Country ..... 373

Table 36 Blood by Country..... 375

Table 37 Meningitis/Encephalitis by Country..... 377

Table 38 Sexually Transmitted Disease by Country ..... 379

Table 39 Other by Country..... 381

Table 40 Hospital Lab by Country ..... 384

Table 41 Outpatient Lab by Country ..... 386

Table 42 Point of Care by Country ..... 388

Table 43 Other by Country..... 390

Table 44 Instruments by Country ..... 393

Table 45 Cartridges by Country..... 395

Table 46 Reagents by Country ..... 397

Table 47 Other Product by Country ..... 399

Table 48 2021 Clinical Lab Fee Schedule ..... 402

Table of Figures

Figure 1 Market Share of Leading Companies Chart ..... 30

Figure 2 The Global Healthcare Spending Picture..... 39

Figure 3 The Lab Test Pie ..... 40

FIGURE 4 STRUCTURE OF CORONAVIRUSES ..... 44

Figure 5 HIV Virion ..... 59

Figure 6 Diagram of the HIV Replication Cycle ..... 63

Figure 7 The Structure of the HBV Virus..... 82

Figure 8 Hepatitis B Replication ..... 83

Figure 9 Structure of the HCV Virus..... 90

Figure 10 HCV Replication Cycle ..... 93

Figure 11 Structure of the Influenza Virion ..... 114

Figure 12 Influenza Replication..... 115

Figure 13 Scanning Electronmicrograph of Tuberculosis..... 144

Figure 14 Chart Death Rates and Infectious Disease Decline ..... 177

Figure 15 Comparing Syndromic and Targeted Testing..... 182

Figure 16 The Multiplex Paradigm Shift..... 183

Figure 17 Global Market Share Chart ..... 350

Figure 18 Global Market by Syndrome - Base vs. Final ..... 352

Figure 19 Global Market by Syndrome Base Year ..... 353

Figure 20 Global Market by Syndrome End Year ..... 354

Figure 21 Syndrome Share by Year ..... 355

Figure 22 Syndrome Segments Growth..... 356

Figure 23 Global Market by Place - Base vs. Final..... 358

Figure 24 Global Market by Place Base Year ..... 359

Figure 25 Global Market by Place End Year ..... 360

Figure 26 Place Share by Year..... 361

Figure 27 Place Segments Growth ..... 362

Figure 28 Global Market by Product - Base vs. Final..... 365

Figure 29 Global Market by Product Base Year ..... 366

Figure 30 Global Market by Product End Year..... 367

Figure 31 Product Share by Year ..... 368

Figure 32 Product Segments Growth ..... 369

Figure 33 Respiratory Growth..... 372

Figure 34 Gastrointestinal Diagnostics Growth..... 374

Figure 35 Blood Growth..... 376

Figure 36 Meningitis/Encephalitis Growth ..... 378

Figure 37 Sexually Transmitted Disease Growth ..... 380

Figure 38 Other Growth..... 382

Figure 39 Hospital Lab Growth..... 385

Figure 40 Outpatient Lab Growth ..... 387

Figure 41 Point of Care Growth ..... 389

Figure 42 Other Growth..... 391

Figure 43 Instruments Growth ..... 394

Figure 44 Cartridges Growth..... 396

Figure 45 Reagents Growth ..... 398

Figure 46 Other Product Growth ..... 400